HUMAN GROWTH HORMONE RELEASING FACTOR IN LONG TERM TREATMENT OF CHILD

儿童长期治疗中的人类生长激素释放因子

• 批准号: 6308580
• 负责人: STEPHEN M ROSENTHAL
• 金额: $ 1.75万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6308580
• 关键词: child (0-11); child physical development; clinical research; endocrine disorder; growth hormone releasing hormone; hormone therapy; human subject; human therapy evaluation; postnatal growth disorder; somatotropin

The primary objective of this study is to evaluate the tolerability and efficacy of the once-a-day subcutaneous administration of GRF 1-44 during 12-24 months in stimulating growth velocity in children with documented growth hormone secretion deficiency of hypothalamic origin. This study, sponsored by ICN Pharmaceuticals, Inc, is a Phase III, single daily administration, non-randomized, open, outpatient study, with each patient serving as his/her own control. Efficacy will be assessed after 6 months based on growth rate.

本研究的主要目的是评估GRF 1-44在12-24个月内每天一次皮下给药刺激下丘脑来源的生长激素分泌不足的儿童生长速度的耐受性和有效性。这项研究由ICN制药公司赞助，是一项III期研究，每天单次给药，非随机，开放，门诊研究，每个患者作为他/她自己的对照。6个月后根据生长速度评估疗效。